Severe, but not mild to moderate, non-alcoholic fatty liver disease associated with increased risk of subclinical coronary atherosclerosis

Hsiao, Chia-Chi; Teng, P. S.; Wu, Yun-Ju; Shen, Yiwen; Mar, Guang-Yuan; Wu, Fu-Zong

doi:10.1186/s12872-021-02060-z

Cited by 16 publications

(15 citation statements)

References 44 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our control group, the rs2728127 polymorphism was associated with a decreased risk of having fatty liver. Evidence suggests that OPN plays an essential role in liver diseases [ 60 , 61 ], including fatty liver, which is linked to atherosclerotic cardiovascular pathology [ 62 ], as well as subclinical atherosclerosis [ 63 ]. Recently, this molecule has also been associated with the presence of cardiac arrhythmias [ 64 ].…”

Section: Discussionmentioning

confidence: 99%

Osteopontin Gene Polymorphisms Are Associated with Cardiovascular Risk Factors in Patients with Premature Coronary Artery Disease

et al. 2021

View full text Add to dashboard Cite

Osteopontin (OPN) is considered a clinical predictor of cardiovascular disease. We aimed to evaluate the association of the OPN gene polymorphisms rs2728127 and rs11730582 with the development of premature coronary artery disease (pCAD), cardiovascular risk factors, and cardiometabolic parameters. We evaluated 1142 patients with pCAD and 1073 controls. Both polymorphisms were determined by Taqman assays. Similar allele and genotype frequencies were observed in both groups; additionally, an association of these polymorphisms with CAD and cardiometabolic parameters was observed in both groups. In patients with pCAD, the rs11730582 was associated with a high risk of hypoadiponectinemia (OR = 1.300, P additive = 0.003), low risk of hypertension (OR = 0.709, P codominant 1 = 0.030), and low risk of having high non-HDL cholesterol (OR = 0.637, P additive = 0.038). In the control group, the rs2728127 was associated with a low risk of fatty liver (OR = 0.766, P additive = 0.038); while the rs11730582 was associated with a low risk of hypoadiponectinemia (OR = 0.728, P dominant = 0.022), and risk of having elevated apolipoprotein B (OR = 1.400, P dominant = 0.031). Our results suggest that in Mexican individuals, the rs11730582 and rs2728127 OPN gene polymorphisms are associated with some abnormal metabolic variables in patients with pCAD and controls.

show abstract

Section: Discussionmentioning

confidence: 99%

Osteopontin Gene Polymorphisms Are Associated with Cardiovascular Risk Factors in Patients with Premature Coronary Artery Disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…28,30 The remaining 12 studies leveraged US to gauge the steatosis gra des. 16,[18][19][20][21][22][23]25,26,29,32,33 The assessment of subclinical atherosclerosis witnessed varied approaches within the included studies. Four studies harnessed IMT scores to evaluate atherosclerosis, 29,30,32,33 whereas three opted for Brachial-ankle pulse wave velocity (BaPWV), 17,23,34 one study employed augmentation index at 75 beats per minute (AI@75) for this purpose, 24 another used cardio-ankle vascular index (CAVI) 27 and the remaining 10 used CAC.…”

Section: Measurement Of Steatosis and Subclinical Atherosclerosismentioning

confidence: 99%

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease

Jamalinia,

Zare,

Noorizadeh

et al. 2024

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackgroundMetabolic dysfunction‐associated steatotic liver disease (MASLD) is a prevalent liver condition recognised as an independent risk factor for cardiovascular disease (CVD). However, there is ongoing debate regarding the effective strategy for cardiovascular risk assessment in MASLD.AimTo investigate the relationship between liver imaging, specifically focusing on the severity of steatosis and subclinical atherosclerosis.MethodsWe conducted a thorough search across four databases, from 1950 to April 2023, to identify eligible studies employing imaging to explore the relationship between different degrees of steatosis and subclinical atherosclerosis among MASLD. Additionally, we conducted a quality assessment using the Newcastle Ottawa Scale, performed a meta‐analysis employing the DerSimonian‐Liard random‐effects model, and conducted subgroup analyses for validation.ResultsIn total, 19 studies, encompassing 147,411 middle‐aged individuals without previous CVD (74.94% male; mean age 45.53 years [SD 10.69]; mean BMI 24.3 kg/m2 [SD 3.35]), were included. The pooled odds ratio for subclinical atherosclerosis was 1.27 (95% CI: 1.13–1.41, I2 = 76.68%) in mild steatosis and significantly increased to 1.68 (95% CI: 1.41–2.00, I2 = 89.02%) in moderate to severe steatosis. Sensitivity analysis, focusing on high‐quality studies, consistently supported this finding and the results remained robust across subgroup analyses. Furthermore, meta‐regression revealed that a higher mean AST and ALT, alongside a lower mean HDL, were significant moderators of this association.ConclusionsEven mild steatosis is associated with CVD risk, and steatosis severity further intensifies this association. These findings suggest that liver fat quantification enhances CVD risk stratification in patients with MASLD.

show abstract

“…Other nonlipoprotein biomarkers of metabolic syndrome are summarized in Table 2[83–90,91 ▪ ,92,93–100,101 ▪ ,102,103–107].…”

Section: Novel Cardiovascular Risk Factors and Metabolic Syndromementioning

confidence: 99%

Established and potential cardiovascular risk factors in metabolic syndrome: Effect of bariatric surgery

Bashir,

Adam,

et al. 2023

Current Opinion in Lipidology

View full text Add to dashboard Cite

Purpose of review The aim of this study was to provide an overview of the role of novel biomarkers in metabolic syndrome, their association with cardiovascular risk and the impact of bariatric surgery on these biomarkers. Recent findings Metabolic syndrome encompasses an intricate network of health problems, and its constituents extend beyond the components of its operational definition. Obesity-related dyslipidaemia not only leads to quantitative changes in lipoprotein concentration but also alteration in qualitative composition of various lipoprotein subfractions, including HDL particles, rendering them proatherogenic. This is compounded by the concurrent existence of obstructive sleep apnoea (OSA) and nonalcoholic fatty liver disease (NAFLD), which pave the common pathway to inflammation and oxidative stress culminating in heightened atherosclerotic cardiovascular disease (ASCVD) risk. Bariatric surgery is an exceptional modality to reverse both conventional and less recognised aspects of metabolic syndrome. It reduces the burden of atherosclerosis by ameliorating the impact of obesity and its related complications (OSA, NAFLD) on quantitative and qualitative composition of lipoproteins, ultimately improving endothelial function and cardiovascular morbidity and mortality. Summary Several novel biomarkers, which are not traditionally considered as components of metabolic syndrome play a crucial role in determining ASCVD risk in metabolic syndrome. Due to their independent association with ASCVD, it is imperative that these are addressed. Bariatric surgery is a widely recognized intervention to improve the conventional risk factors associated with metabolic syndrome; however, it also serves as an effective treatment to optimize novel biomarkers.

show abstract

Severe, but not mild to moderate, non-alcoholic fatty liver disease associated with increased risk of subclinical coronary atherosclerosis

Cited by 16 publications

References 44 publications

Osteopontin Gene Polymorphisms Are Associated with Cardiovascular Risk Factors in Patients with Premature Coronary Artery Disease

Osteopontin Gene Polymorphisms Are Associated with Cardiovascular Risk Factors in Patients with Premature Coronary Artery Disease

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease

Established and potential cardiovascular risk factors in metabolic syndrome: Effect of bariatric surgery

Contact Info

Product

Resources

About